Autopsy report · NCT03241927

Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)

“difficult enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 6 months before it stopped.
• 1 participant enrolled.
• Results were posted on the registry 2 years 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Nina Bhardwaj

Sponsor type

University, hospital or other

Conditions

Melanoma

Interventions

Pembrolizumab

Participants

1

Sites

1

Countries

United States

Trials that died the same way

• A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy
  “difficulty in enrollment” (95% match in meaning)
• Maintenance Dosing of Vitamin D in Crohn's Disease
  “Difficulties with enrollment” (94% match in meaning)
• Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts
  “Difficulties of enrollment” (93% match in meaning)
• Effectiveness and Safety of Spondylitis Related to Inflammatory Bowel Disease
  “Difficulty with enrollment” (93% match in meaning)
• Clinical Trial With Mesalamine 1g Suppositories
  “Enrollment difficulties” (92% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.